Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.76 USD 1.47% Market Closed
Market Cap: 815.2m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Abcellera Biologics Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abcellera Biologics Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Long-Term Debt
CA$500k
CAGR 3-Years
-47%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Long-Term Debt
CA$41k
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Long-Term Debt
CA$100k
CAGR 3-Years
71%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abcellera Biologics Inc
Glance View

Market Cap
802.7m USD
Industry
Life Sciences Tools & Services

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.67 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Long-Term Debt?
Long-Term Debt
0 USD

Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Long-Term Debt amounts to 0 USD.

Back to Top